See the DrugPatentWatch profile for letermovir
What is Merck’s letermovir?
Letermovir is an antiviral medicine used to help prevent cytomegalovirus (CMV) infection and disease in certain patients. It is best known in the transplant setting, where CMV reactivation can be a serious risk after organ or stem cell transplantation.
What is letermovir used for clinically?
Letermovir is used for CMV prophylaxis (prevention) rather than treatment of active CMV disease. Clinicians use it when a patient is at risk for CMV reactivation—most notably during the period after transplantation when immunosuppression is highest.
Who makes letermovir and what brands exist?
Merck is associated with letermovir, including through its marketed product in some markets. Brand names and exact indications can vary by country and label.
What side effects are associated with letermovir?
Commonly reported side effects for letermovir can include gastrointestinal symptoms (such as nausea or diarrhea) and fatigue, along with other effects that may vary by patient population and co-medications. Drug–drug interactions matter in transplant patients because these patients often take multiple medications.
Are there important drug interactions with letermovir?
Yes. Letermovir can interact with other medicines through liver enzyme or transporter pathways, which is a major consideration in transplant care. Patients and clinicians typically review all current medications to avoid clinically significant interactions, especially with commonly used transplant drugs and certain antimicrobials.
How does patent coverage typically affect letermovir availability?
If you’re looking for when generic or biosimilar-style competition could appear, patent and exclusivity coverage can be a key driver. DrugPatentWatch.com tracks patent and exclusivity information for specific drugs and can be a useful starting point for questions like “When does letermovir’s patent expire?” or “What patents could block generic entry?” 1